George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
So we have at least 3 reasons to be cautiously optimistic TW the progress of the AVA6K trials:
Al was very pleased with progress to date when reporting on the 30th; the strengthening of the therapeutics side of the management team with oncology experts since first dosage back in August; the recent opening up of recruitment to the trials in 3 further hospitals.
The very best of luck to all those patients who volunteered to take part in these trials
Why are we obsessing about Ndn when we have it now confirmed that we have a 4th hospital at Weston Park who are now recruiting for AVA6k
https://i3.energy/wp-content/uploads/2021/10/211019_I3E-Sitting-pretty.pdf
Unlike some on here I welcome Ophidian’s comments particularly as he has now seemed to have toned down his arrogance. He has again tweeted today of possible good news in the offing which as his critics have laboriously pointed out he predicted at the end of September. The one predictable occurrence with Avacta is the the impossibility of accurately predicting timings
I am sure that you speak for the frustrated majority who have to put up with their daily whinging every time the SP isn’t rising. What a truly miserable existence they must lead!
Yes I thought it was a comment from Align but it is actually from the Aquis stock exchange but it is good to see they are commenting on the potential of one of their stocks
https://mobile.twitter.com/AquisStockEx/status/1445660096999067648/photo/1
Analyst update
Ask yourself why a person with such a personal and professional back story should now concentrate her efforts on the oncology work of a small UK bio company based in Wetherby and Cambridge.
Yes it’s right to draw a distinction here between therapeutics and diagnostics regarding expectations and timelines. Al has been criticised for over optimistic timelines regarding the rolling out of the LFD but he has been let down badly by factors outside its control not least the actions of HMG. When it comes to the science which AVCT can control it has produced one of the most accurate tests on the market. With the cancer trials there is much less opportunity for outside factors like HMG intervention to impede progress. Hopefully there will be fewer unnecessarily spiteful comments aimed in the direction of Al and his wonderful team as they progress the company over the coming months to something which potentially could have a global impact
Good to see the SP finally responding to the potential that a few of us have known about for some time. Little doubt now that this potential with fairly regular news flow is now becoming more widely known
No surprise it would be LUFC given AVCT’s close links to Leeds University
In relation to the query regarding the possible squeeze on profit margins due to a saturated market, it was made very clear in the Presentation that our higher quality test would enable us to set a higher price without affecting market share
In the slide on LFD Medusa was mentioned in the last bullet point. Al emphasised that it’s potential significance was more important than the other manufacturers referenced. HUA for Medusa appears to be inevitable and possibly imminent and it is highly unlikely news of this is in the present SP.
Have you ever been positive about AVCT Roly? You have zero credibility. Welcome to the green box
Abingdon producing batched products for sale now
Very pleased with progress to date
3 more AVA6k sites coming on line
It was the type of report that could have been anticipated but no worse for that. The 2 big takeaways for me was the £37 million cash available and the second and third doses administered at the Royal Marsden
Further reference to the price of our LFD being above cheaper alternatives because of the quality of our product.